Final Thoughts on Type 1 Diabetes: Innovations, Challenges and the Road Ahead
A panelist discusses how the adoption of C-peptide preservation as a critical end point in clinical trials represents a paradigm shift in type 1 diabetes (T1D) research, moving beyond glucose control alone to focus on disease-modifying therapies that can maintain endogenous insulin production and potentially alter the fundamental course of the disease.
Video content above is prompted by the following:
- Many emerging therapies are using C-peptide levels as an end point for assessing efficacy. How does this shift impact treatment strategies and clinical research in T1D?
- If there is one key message you would like health care decision-makers to take away from this discussion regarding T1D, what would it be?
- To close our interview, what are some promising avenues for future research and innovation in the field of T1D? What are you most excited about in the future?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
